SANTA CLARA, Calif., September 20, 2018 – SI-BONE, Inc.(“SI-BONE”), a medical device company that pioneered the minimally invasive surgical treatment of the sacroiliac joint with the iFuse Implant System®, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. SI-BONE has applied to list its common stock on The Nasdaq Global Market under the ticker symbol "SIBN”.
Morgan Stanley and BofA Merrill Lynch are acting as joint book-running managers. Canaccord Genuity LLC and JMP Securities LLC are acting as co-managers.
The proposed offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or email at prospectus@morganstanley.com; or from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, or email at dg.prospectus_requests@baml.com.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Investor Contacts:
Lynn Lewis or Carrie Mendivil
Gilmartin Group LLC
investors@SI-BONE.com
415-937-5405
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All opinions, forecasts, projections, future plans or other statements, other than statements of historical fact, are forward-looking statements. Forward-looking statements involve risks and uncertainties, including uncertainties regarding the timing and terms of the proposed offering described in this press release and the impact it may have on SI-BONE, and the risk that the proposed offering may not be completed. Forward-looking statements speak only as of the date of this press release, and SI-BONE does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or for any other reason, except as required by law.